A 6 Week Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD ( Attention Deficit/Hyperactivity )

Completed · Phase 2/Phase 3 · Has a placebo group

Conditions studied: ADHD, Attention-Deficit/Hyperactivity Disorder, Predominantly Inattentive Type

In brief

This study is a multisite, randomized, double-blind, placebo-controlled, phase 2/3 study of MG01CI (1400 mg daily) for 6 weeks compared with placebo in a 1:1 ratio of 300 adults with ADHD.

Key facts

Study ID

NCT02059642

Run by

Alcobra Ltd.

People needed

300

Starts

2014-03-01

Expected to finish

2014-09-01

Last updated by the study team

2017-03-28

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subject is a man or a non-pregnant, non-lactating woman 18 to 55 years of age, inclusive, at the Screening Visit.
• Subject has a diagnosis of ADHD based on criteria in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) and DSM5.
• Subject has ADHD with at least moderate clinical severity (Clinical Global Impression-Severity [CGI-S]) score of 4 or greater).
• Subject has a score on the total ADHD symptom score with adult prompts of the CAARS-Inv of at least 22.
• Female subjects of childbearing potential must agree to use an effective contraceptive throughout the study
• Subject is able to attend the clinic regularly and reliably.
• Subject is able to swallow tablets and capsules.
• Subject is able to understand, read, write, and speak English fluently to complete the study-related materials (or Hebrew for Israeli subjects).
• Subject is able to understand and sign an informed consent form to participate in the study.

You may not qualify if…

• Subject did not respond in the past to 2 adequate trials of stimulant treatments or 1 adequate trial of atomoxetine treatment (in the investigator's judgment).
• Subject has any psychiatric condition clinically significant or unstable medical or surgical condition that may preclude safe and complete study participation as determined by the investigator .
• Subject has a known or suspected human immune deficiency virus-positive status or has diseases such as acquired immunodeficiency disorder, hepatitis C, hepatitis B, or tuberculosis.
• Subject has a history of an allergy or sensitivity to B-complex vitamins.
• Subject has a history of intellectual disability or a history or suspicion of autism spectrum disorder.
• Subject has a current Axis I diagnosis (other than ADHD) according to the Structured Clinical Interview for DSM IV Axis I Disorders (SCID) or has a lifetime history of bipolar disorder or psychosis.
• Subject has used mega-dose vitamin B6/pyridoxine during the 28 days before the Screening Visit.
• Subject has used high-dose supplements of omega-3 fatty acids ≥ 500 mg on at least 1 day or folic acid supplements during the 2 weeks before the Screening Visit.
• Subject has used an investigational medication/treatment in the 30 days before the Screening Visit
• Subject has used any medication or food supplement that the investigator or the medical monitor considers unacceptable during the 14-day period before randomization.
• Subject has a current drug or alcohol dependence or substance abuse disorder according to DSM-IV. Subject should also agree to keep their caffeine intake consistent and refrain from consuming ≥300 mg per day of caffeine (no more than three 8-ounce servings of coffee) during the study.
• Subject has suicidality, defined as active ideation, an intent or plan, or any significant lifetime suicidal behavior. Subjects exhibiting history (within previous 12 months) of non-suicidal self-injurious behavior will be excluded.
• Subject has taken any prescription or non-prescription ADHD medications during the 14 days (for all psychotropic medications other than fluoxetine) or 28 days (for fluoxetine) before the randomization visit.
• Subject is significantly visually impaired to an extent that is not able to be corrected by prescription glasses or contact lenses
• Subject is related to the sponsor, investigator, or study staff.
• Subject has any condition that, in the principal investigator's opinion, would place the subject at risk or influence the conduct of the study or interpretation of results,
• Subject cannot fully comprehend the implications of the protocol, cannot comply with its requirements, or is incapable of following the study schedule for any reason.
• Subject is pregnant, lactating, or using an inadequate contraceptive method.
• If there is a ≥25% change in the CAARS-Inv results between the Interim visit (off drug) assessment and the Baseline assessment, or if the subject does not return for the Baseline CAARS-Inv assessment, the subject will not be randomized. For subjects not needing washout, if there is a ≥25% change in the CAARS-Inv results between the Screening Visit assessment and the Baseline assessment, or if the subject does not return for the Baseline CAARS-Inv assessment, the subject will not be randomized.

Where it is running

• Sarkis Clinical Trials — Gainesville, Florida, United States
• Miami Research — South Miami, Florida, United States
• Capstone Clinical Research — Libertyville, Illinois, United States
• Psychiatric Associates — Overland Park, Kansas, United States
• University Kentucky Psychiatry — Lexington, Kentucky, United States
• Pediatric Psychopharmacology & Adult ADHD Program, Massachusetts General Hospital — Boston, Massachusetts, United States
• Rochester Center For Behavioral Medicine — Rochester Hills, Michigan, United States
• Behavioral Medicine Center — Troy, Michigan, United States
• St. Charles Psychiatric Associates — Saint Charles, Missouri, United States
• Center for Psychiatry and Behavioral Medicine — Las Vegas, Nevada, United States
• Bioscience Research — Mount Kisco, New York, United States
• Duke University — Durham, North Carolina, United States
• Richard H Weisler, MD, PA — Raleigh, North Carolina, United States
• Sequoia Behavioral Healthcare — Media, Pennsylvania, United States
• FutureResearch Trials — Austin, Texas, United States
• FutureResearch Trials Dallas, LP — Dallas, Texas, United States
• Bayou City Research — Houston, Texas, United States
• NeuroScience, Inc. (NSI) — Herndon, Virginia, United States
• Neurocognitive unit Rambam MC — Haifa, Israel
• ADHD unit Geha MC — Petah Tikva, Israel

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.